Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis - Barth, P.; Bruijnzeel, P.; Wach, A.; Sellier Kessler, O.; Hooftman, L.; Zimmermann, J.; Naue, N.; Huber, B.; Heimbeck, I.; Kappeler, D.; Timmer, W.; Chevalier, E. (Journal of cystic fibrosis, 2020)
Keywords: Cystic fibrosis; Inflammation; Inhalation; Neutrophil elastase inhibitor; Pharmacokinetics; Pulmonary/Respiratory; Safety; Cystic fibrosis; Inflammation; Safety; Pharmacokinetics; Neutrophil elastase inhibitor; Inhalation